The therapeutic community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 receptor that’s demonstrating significant efficacy in clinical trials for treating obesity. Unlike some current weight loss solutions, retatrutide appears to offer a greater substantial loss in body size and improve metabolic markers, partic